ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Sjogren’s syndrome"

  • Abstract Number: L20 • 2013 ACR/ARHP Annual Meeting

    Association Between Germinal Center Formation in Labial Salivary Gland Biopsies and Predictors of Lymphoma Among Participants of the Sjӧgren’s International Collaborative Clinical Alliance (SICCA)

    Annie Chou1, Kimberly E. Taylor2, Richard C.K. Jordan3, John S. Greenspan4, Troy E. Daniels4, Caroline H. Shiboski1 and Lindsey A. Criswell5,6, 1Orofacial Sciences, University of California San Francisco, San Francisco, CA, 2Department of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, 3Orofacial Sciences, Pathology, & Radiation Oncology, University of California San Francisco, San Francisco, CA, 4Orofacial Sciences & Pathology, University of California San Francisco, San Francisco, CA, 5University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, 6University of California, San Francisco, Department of Medicine, San Francisco, CA

    Background/Purpose: Sjӧgren’s Syndrome (SS) is a chronic autoimmune disease characterized by lymphocytic infiltration of the lacrimal and salivary glands causing dry eyes and dry mouth. …
  • Abstract Number: 2770 • 2013 ACR/ARHP Annual Meeting

    Complex Functional Effects Within The HLA Contribute To Sjögren’s Syndrome Pathogenesis and May Influence Both Transcriptional Regulation and Peptide Binding

    Christopher J. Lessard1,2, He Li1, Indra Adrianto1, John A. Ice1, Mikhail G. Dozmorov3, Roland Jonsson4, Maureen Rischmueller5, Gunnel Nordmark6, Xavier Mariette7, Corinne Miceli-Richard8, Marie Wahren-Herlenius9, Torsten Witte10, Michael T. Brennan11, Roald Omdal12, Lars Rönnblom13, Patrick M. Gaffney1, Wan-Fai Ng14, Nelson L. Rhodus15, Barbara M. Segal16, Jonathan D. Wren1, R. Hal Scofield1,17,18, Juan-Manuel Anaya19, John B. Harley20,21, Courtney G. Montgomery1 and Kathy L. Sivils1,2, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Arthritis and Clincial Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, 5Rheumatology Department, Queen Elizabeth Hospital, Adelaide, Australia, 6Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 7Paris-Sud University, Paris, France, 8Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, 9Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 10Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, 11Nidcr NIH, Carolinas Medical Center, Charlotte, NC, 12Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, 13Department of Medical Science, Uppsala University, Uppsala, Sweden, 14Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle upon Tyne, United Kingdom, 15University of Minnesota, Minneapolis, MN, 16Rheumatology, Hennepin County Medical Center, Minneapolis, MN, 17Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 18US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 19School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, 20Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 21US Department of Veterans Affairs Medical Center, Cincinnati, OH

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is a common, heterogeneous exocrinopathy.  Etiology involves complex environmental, genetic and genomic influences driving innate and adaptive autoimmune responses.  This…
  • Abstract Number: 851 • 2013 ACR/ARHP Annual Meeting

    Salivary Gland Ultrasonography Improves The Diagnostic Performance Of ACR 2012 Classification Criteria For Sjögren’s Syndrome, Even In The Early Stages Of The Disease

    Divi Cornec1, Sandrine jousse-Joulin2, Thierry Marhadour3, Jacques-Olivier Pers4, Yves Renaudineau4, Alain Saraux5 and Valerie Devauchelle-Pensec6, 1Department of rheumatology, Brest Occidentale University, Brest, France, 2Rheumatology, Brest university medical school, EA 2216, UBO and CHU de la Cavale Blanche,, Brest, France, 3Rheumatology, CHU de la Cavale Blanche, Brest, France, 4Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, 5Department of rheumatology and unit of immunology (EA 2216), CHU Brest et Université Bretagne Occidentale, Brest, France, 6Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France

    Background/Purpose: Recently published ACR classification criteria for primary Sjögren’s syndrome (pSS) include only 3 objective tests: 1) a serological item: anti-SSA/SSB antibodies or [antinuclear antibody…
  • Abstract Number: 2772 • 2013 ACR/ARHP Annual Meeting

    Identification Of a Sjögren’s Syndrome-Associated Variant That Influences OAS1 Isoform Switching

    He Li1,2, John A. Ice3, Jennifer A. Kelly3, Indra Adrianto1, Stuart B. Glenn3, Kimberly S. Hefner4, Evan G. Vista5, Donald U. Stone6, Raj Gopalakrishnan7, Glen D. Houston8, David M. Lewis9, Michael Rohrer7, Pamela Hughes7, John B. Harley10,11, Courtney G. Montgomery3, James Chodosh12, James A. Lessard13, Juan-Manuel Anaya14, Barbara M. Segal15, Nelson L. Rhodus16, Lida Radfar2, R. Hal Scofield17, Christopher J. Lessard3,18 and Kathy L. Sivils1, 1Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Hefner Eye Care and Optical Center, Oklahoma City, OK, 5Rheumatology and Clinical Immunology, University of Santo Tomas, Taguig City, Philippines, 6Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 7Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, 8Collage of Denistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 9College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 10Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 11US Department of Veterans Affairs Medical Center, Cincinnati, OH, 12Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, 13Valley Bone and Joint Clinic, Grand Forks, ND, 14Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, 15Rheumatology, Hennepin County Medical Center, Minneapolis, MN, 16University of Minnesota, Minneapolis, MN, 17Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 18Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose: Sjögren’s syndrome (SS) is a common, progressive autoimmune exocrinopathy characterized by symptoms of dry eyes and mouth present in 0.7-1% of the European population.…
  • Abstract Number: 522 • 2013 ACR/ARHP Annual Meeting

    Abatacept Reduces Disease Activity In Early Primary Sjögren’s Syndrome:One Year Results From a Phase II Open-Label Study

    PM Meiners1, A Vissink2, Fkl Spijkervet3, EA Haacke4, WH Abdulahad5, E Brouwer5, MG Huitema5, N Sillevis Smitt-Kamminga6, FGM Kroese7, S Arends5 and H Bootsma5, 1Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 3Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, Netherlands, 4Pathology, University Medical Center Groningen, Groningen, Netherlands, 5Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 6Opthalmology, University Medical Center Groningen, Groningen, Netherlands, 7Rheumatology and clinical immunology, University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Traditional DMARDs have limited effects in primary Sjögren's (pSS) patients. B cell depletion therapy with rituximab showed efficacy, but had some side-effects. T and…
  • Abstract Number: 2774 • 2013 ACR/ARHP Annual Meeting

    Distinct Role Of Plasmacytoid Dendritic Cells and Mast Cells In The Pathogenesis Of Sjӧgren’s Syndrome

    Jidong Zhao1, Kunihiro Yamaoka1, Satoshi Kubo1, Shingo Nakayamada2 and Yoshiya Tanaka1, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan

    Background/Purpose: Sjögren’s Syndrome (SS) is characterized by the destruction of the lacrimal and salivary grands due to autoreactive lymphocyte infiltration in the early phase and…
  • Abstract Number: 505 • 2013 ACR/ARHP Annual Meeting

    Damage Accrual In a Single Centre Cohort Of Patients With Primary Sjögren’s Syndrome Followed Up For Over 10 Years

    Chiara Baldini1, Francesco Ferro1, Pasquale Pepe2, Nicoletta Luciano1, Francesca Sernissi1, Carlotta Cacciatore1, Daniela Martini1, Antonio Tavoni3, Marta Mosca4 and Stefano Bombardieri1, 1University of Pisa, Rheumatology Unit, Pisa, Italy, 2Institute of Clinical Physiology, National Research Council, Pisa, Italy, 3University of Pisa, Immunoallergology Unit, Pisa, Italy, 4Rheumatology Unit, University of Pisa, Pisa, Italy

    Background/Purpose: 1) To describe  the progression and cumulative prevalence of damage accrued over the time in a single center cohort of patients with primary Sjögren’s…
  • Abstract Number: 2775 • 2013 ACR/ARHP Annual Meeting

    Adenosine A2b Receptor Agonist Bay60-6583 Restores Salivary Gland Function In a Mouse Model For Sjögren’s Syndrome

    Barbara Szczerba1, Paulina Rybakowska1, Paromita Dey1, Harini Bagavant1 and Umesh Deshmukh2, 1Department of Medicine, University of Virginia, Charlottesville, VA, 2Medicine, University of Virginia, Charlottesville, VA

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is a chronic autoimmune disorder mainly affecting the exocrine glands. However, it is now clear that both immune and non-immune…
  • Abstract Number: 506 • 2013 ACR/ARHP Annual Meeting

    Hospitalization In Patients With Primary Sjögren’s Syndrome

    Yemil Atisha-Fregoso1, Yahaira Rivera2 and Gabriela Hernandez-Molina2, 1Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubirán, Mexico City, Mexico

    Background/Purpose: There is scant information on the frequency, main causes and associated risk factors of hospitalization in patients with primary Sjögren syndrome (PSS).We aimed to…
  • Abstract Number: 2032 • 2013 ACR/ARHP Annual Meeting

    How Does Age At Onset Influence Autoimmune Rheumatic Diseases?

    Jenny Amaya-Amaya1, Juan-Camilo Sarmiento-Monroy2, Nicolás Molano-González1, Mónica Rodríguez-Jiménez1, Rubén-Darío Mantilla2, Adriana Rojas-Villarraga1 and Juan-Manuel Anaya2, 1Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, 2School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia

    Background/Purpose: Age at onset of disease (AOD) refers to the time period at which a patient experiences the first sign (s) and symptom(s). AOD varies…
  • Abstract Number: 507 • 2013 ACR/ARHP Annual Meeting

    Level Of Agreement Of The AECG 2002 and ACR 2012 Classification Criteria For Sjögren’s Syndrome In The Brittany Cohort: Clues To Understand Discrepancies

    Divi Cornec1, Alain Saraux2, Jacques-Olivier Pers3, Sandrine Jousse-Joulin4, Yves Renaudineau3, Beatrice Cochener5, Thierry Marhadour6 and Valerie Devauchelle-Pensec7, 1Department of rheumatology, Brest Occidentale University, Brest, France, 2Department of rheumatology and unit of immunology (EA 2216), CHU Brest et Université Bretagne Occidentale, Brest, France, 3Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, 4Rheumatology, Brest university medical school, EA 2216, UBO and CHU de la Cavale Blanche,, Brest, France, 5Department of ophtalmology, Brest Occidentale University, Brest, France, 6Rheumatology, CHU de la Cavale Blanche, Brest, France, 7Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France

    Background/Purpose: New classification criteria for primary Sjögren’s syndrome (pSS) have been proposed in 2012 and approved by the ACR. They differ substantially from the currently…
  • Abstract Number: 1844 • 2013 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis, Sjogren’s Syndrome and Systemic Lupus Erythematosus Patients Have a Distinct Spectrum Of Serum Anticytokine Autoantibodies

    Sarthak Gupta1,2, Ioanna P. Tatouli3, Lindsey B. Rosen2, Sarfaraz A. Hasni1, Richard M. Siegel1, Steven M. Holland2, Haralampos M. Moutsopopoulos3 and Sarah K. Browne2, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 3School of Medicine, National University of Athens, Athens, Greece

    Background/Purpose: Anticytokine autoantibodies are pathogenic in many hematologic, pulmonary and infectious diseases. However, the prevalence and significance of anticytokine autoantibodies in rheumatic conditions is poorly…
  • Abstract Number: 508 • 2013 ACR/ARHP Annual Meeting

    Is Ultrasonography Of Salivary Gland a Validate Tool In Sjögren Syndrome? Study 1: Interobserver Reliability Between International Group Of Experts

    Sandrine Jousse-Joulin1, Vera Milic2, Elke Theander3, Malin V. Jonsson4, Wan-Fai Ng5, Chiara Baldini6, Marina Carotti7, Alan N. Baer8, Joel Fradin9, Pascale Rachele10, Hendrika Bootsma11, Jacqueline Brown12, Nicoletta Luciano6, S Bombardieri13, Roland Jonsson14, Salvatore De Vita15, Alojzija Hocevar16, Matija Tomsic17,18, Alain Saraux19, Emmanuel Nowak20, Alessandro Ciapetti Sr.21, Arjan Vissink22, John Rout23, Thomas Mandl24, Simon J. Bowman25 and Valerie Devauchelle-Pensec26, 1Rheumatology, Brest university medical school, EA 2216, UBO and CHU de la Cavale Blanche,, Brest, France, 2rheumatology, belgrade university, belgrade, Serbia, 3Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 4Department of Clinical Dentistry - Section for Oral and Maxillofacial Radiology, University of Bergen, Bergen, Norway, 5Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, 6University of Pisa, Rheumatology Unit, Pisa, Italy, 7Rheumatology and radiology, Ospedali Riuniti, Ancona, Italy, 8Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 9Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, 10radiology, university of Pisa, Pisa, Italy, 11Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 12dental division, Tower Wing Guy's hospital, london, United Kingdom, 13Department of Clinical and Experimental Medicine, Department of Rheumatology, University of Pisa, Pisa, Pisa, Italy, 14Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, 15Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, 16Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 17Department of Rheumatology, BioRx.si, University Medical Centre Ljubjana, Ljubljana, Slovenia, 18Faculty of Medicine, Unversity Ljubljana, Ljubljana, Slovenia, 19Department of rheumatology and unit of immunology (EA 2216), CHU Brest et Université Bretagne Occidentale, Brest, France, 20CIC, CHU Brest, Brest, France, 21Department of Rheumatology, Politechnic University of the Marche, Ancona, Ancona, Italy, 22Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 23Birmingham Dental Hospital, Birmingham, United Kingdom, 24Dept of Rheumatology, Skåne University Hospital Malmo, Lund University, Sweden, Malmö, Sweden, 25Department of Rheumatology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom, 26Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France

    Background/Purpose: Ultrasonography (US) of salivary glands is a relatively new test to diagnose primary Sjögren syndrome (pSS)1-6. In 2012, an international group of interest was…
  • Abstract Number: 1656 • 2013 ACR/ARHP Annual Meeting

    Interferon Type I and T Helper 17: A Dangerous Liaison In Primary Sjögren’s Syndrome?

    Zana Brkic1, Sandra M.J. Paulissen2, Cornelia G. van Helden-Meeuwsen3, Naomi I. Maria3, Odilia B.J. Corneth4, Nadine Davelaar5, Jan Piet van Hamburg5, Paul L. Van Daele3, Virgil A. Dalm1, Martin van Hagen3, Erik Lubberts6 and Marjan A. Versnel1, 1Erasmus Medical Center, Immunology, Rotterdam, Netherlands, 2Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, 3Immunology, Erasmus Medical Center, Rotterdam, Netherlands, 4Rheumatology and Immunology, Erasmus Medical Center, Rotterdam, Netherlands, 5Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 6Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands

    Background/Purpose: The T helper 17 (Th17) cell subset, which produces IL-17A, IL-17F, IL-22 and IL-21, has been implicated in the pathogenesis of primary Sjögren’s syndrome…
  • Abstract Number: 510 • 2013 ACR/ARHP Annual Meeting

    Multicentric Analysis Of Inter and Intra Observer Reliabilities For Histopathological Abnormalities In Salivary Gland Biopsy In Primary Sjögren Syndrome

    Sebastian Costa1, Isabelle Quintin Roue2, Agnes Lesourd2, Sandrine Jousse-Joulin3, Pascale Marcorelles4, Eric Hachulla5, Vincent Goeb6, Marie-Christine Copin7, Jean-Marie Berthelot8, Jacques-Olivier Pers9, Olivier Vittecoq10, Emmanuel Nowak11, Alain Saraux12 and Valerie Devauchelle-Pensec13, 1anatomopathological department, Brest university hospital, Brest, France, 2anatomopathological department, Morvan hospital, Brest, France, 3Rheumatology, Brest university medical school, EA 2216, UBO and CHU de la Cavale Blanche,, Brest, France, 4anatomopathological department, Brest university hospital, CHU Morvan, Brest, France, 5Internal Medicine, Lille CEDEX, France, 6Rheumatology, Amiens University Hospital, Amiens, France, 7anatomopathological department, Lille university, Lille, France, 8Rheumatology Unit, Nantes University Hospital, Nantes, France, 9Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, 10Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, 11CIC, CHU Brest, Brest, France, 12Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, 13Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France

    Background/Purpose: : Histopathologic evaluation of minor labial salivary gland (MLSG) is a major goal for the classification of patients with a primary Sjögren syndrome (pSS)…
  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology